Altimmune's Pemvidutide Reduces Heavy Drinking Days in Phase 2 Trial

Bitget2026/11/05 15:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Altimmune will present RECLAIM Phase 2 pemvidutide results for alcohol use disorder at AASLD’s The Liver Meeting on Nov. 9, 2026.
Topline results announced in July showed reduced heavy drinking versus placebo, met key secondary goals and indicated generally favorable tolerability.
An FDA meeting scheduled for December will address the Phase 3 registration program for pemvidutide in alcohol use disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051000PRIMZONEFULLFEED9870534) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Altimmune's Pemvidutide Reduces Heavy Drinking Days in Phase 2 Trial

You may also like

Crypto prices